Octarine Bio, the synthetic biologic drug development company that produces psilocybin from sugar using fermentation, is partnering with clinical research organization Clerkenwell Health to conduct clinical trials.
– Europe the psychedelic healthcare business ecosystem is growing, building on a strong legacy of academic and civil society support
– A partnership between these two innovative startups paves the way for improving patient access to psychedelic drugs in Europe
– Octarine Bio uses yeast fermentation to produce psilocybin from sugar which has many advantages such as low cost, sustainability and supply chain stability
– Clerkenwell Health is well positioned to accelerate the psychedelic industry by offering specialized clinical research support services backed by world-renowned clinical researchers in the psychedelic field and with its soon to be launched Center of Research Excellence
LONDON, September 8, 2021 / PRNewswire / – With successful innovative companies across the continent, Europe is emerging as a psychedelic hub, attracting ideas, capital and general support. Collaborations are starting to strengthen the commercial ecosystem for the development of psychedelic drugs.
Copenhagensynthetic biology company, Octarine Bio, backed by institutional investors such as Oskare Capital, the Danish State Growth Fund and leading angel investors including Bruce linton, announces a partnership with Clerkenwell Health, a UK-based contract research organization specializing in psychedelics and backed by venture capital fund Vine Ventures and leading UK angel investors, to advance patient access and the quality of psychedelic medicine.
Patients participating in clinical trials will soon be able to receive psilocybin which has been produced in European laboratories for various mental health issues. The psychedelic ecosystem thrives in Europe and business enterprises are accelerating this growth by increasing efficiency in different parts of this ecosystem, from research infrastructure to supply chains.
Clerkenwell Health supports the ecosystem not only in the UK but more broadly in Europe by providing clinical research support to drug developers, while Otarine offers innovative methods to produce natural and novel psychedelic compounds that have been successfully demonstrated at the laboratory scale.
Currently, many trials are being conducted in partnership with universities and hospitals that may have difficulty with the speed and scale needs of their business partners. In addition, they lack the pleasant “frame” commonly attributed to a positive psychedelic experience. Meanwhile, mainstream clinical research organizations are struggling to understand the nuances of psychedelic-assisted therapies in terms of clinical settings and psychotherapies that will achieve optimal patient outcomes.
Tom mcdonald Clerkenwell Health CEO celebrated the partnership by saying “It is a real pleasure to work with Octarine which is at the forefront of the biosynthesis of a range of compounds which should lead to lower costs for patients. They have a strong pedigree in drug development which is a perfect match for the commercial and clinical expertise that we have built within the Clerkenwell Health team “.
Thanks to this partnership, Octarine now has access to the services of Clerkenwell Health to accelerate its clinical development with biosynthetic psilocybin and hopes to be able to accelerate the steps leading to human clinical trials.
A key barrier to increasing the accessibility of psychedelic treatments relates to the limitations associated with the production of psychedelic compounds in the high quality required for clinical development.
Octarine solves this problem by turning to yeast, a microorganism widely known for its use in the production of beer by turning sugar into ethanol. Octarine hijacks this fermentation machinery to transform sugar into psilocybin. This innovative IP-protected production process is easily scalable and highly modular, enabling the production of a range of natural and novel tryptamine psychedelics simply by swapping a few genes.
“Our main ambition at Octarine is to advance psychedelic therapy through Europe and the world in a way that is consistent with the principles of sustainability while ensuring accessibility for patients. We are delighted to be working with Clerkenwell Health who shares our vision and is committed to making Europe a leader in the field by providing world-class clinical expertise tailored to the nuances of psychedelic therapy. “ said Nick Milne PhD, Co-Founder and CSO of Octarine.
For more information or interview requests, please contact:
About Clerkenwell Health
Clerkenwell Health is an innovative UK-based mental health start-up that is creating a platform to accelerate patient access to a range of psychedelic-assisted therapies over the coming years. Clerkenwell Health strives to help its customers generate the clinical data necessary to integrate these exciting treatment methodologies with physicians and regulators.
The team is led by the CEO Tom mcdonald, a former Accenture pharmaceutical specialist specializing in patient-centered care and CSO Dr Henri fisher, chemist and expert in pharmaceutical policy. Patient therapy is led by Dr Sara Tai, clinical psychologist, lecturer in clinical psychology at the University of Manchester and an expert in psychotherapy in clinical trials of psychedelic medicine. www.clerkenwellhealth.com
About Octarine Bio
Octarine Bio’s mission is to solve the greatest health challenges by enabling innovative cannabinoid and psychedelic therapies. Many neurological and psychological disorders are poorly treated with current medications, leaving physicians, patients and their families desperate to seek alternative therapies. Cannabinoids and psychedelics are poised to offer groundbreaking therapies for these debilitating conditions, but to realize the full potential of these molecules, issues with their production and unwanted properties must first be addressed.
Octarine Bio perfects a biological approach to produce improved and new cannabinoid and psychedelic molecules with adapted modes of action. Their proprietary technology combines synthetic biology, yeast fermentation and enzymatic derivatization to develop PI-protected drug candidates that are validated in preclinical models. www.octarinebio.com
Show original content:https://www.prnewswire.com/news-releases/danish-synthetic-biology-drug-developer-octarine-and-british-clinical-research- organization-clerkenwell-health-partner-to-bring-innovative-psychedelics- to-patients-301370823.html
SOURCE Octarine Bio; Clerkenwell Health